{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T08:59:06Z","timestamp":1766048346794,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.urolonc.2012.05.007","type":"journal-article","created":{"date-parts":[[2012,7,4]],"date-time":"2012-07-04T23:53:44Z","timestamp":1341446024000},"page":"1676-1682","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Lenalidomide augments the efficacy of bacillus Calmette-Guerin (BCG) immunotherapy in vivo"],"prefix":"10.1016","volume":"31","author":[{"given":"Goodwin","family":"Jinesh G.","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene Kang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2012.05.007_bib1","first-page":"10","article-title":"Cancer statistics","volume":"2012","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2012.05.007_bib2","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/BF03262330","article-title":"The health economics of bladder cancer: A comprehensive review of the published literature","volume":"21","author":"Botteman","year":"2003","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.urolonc.2012.05.007_bib3","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2012.05.007_bib4","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1200\/JCO.1988.6.9.1450","article-title":"Bacillus Calmette-Guerin therapy alters the progression of superficial bladder cancer","volume":"6","author":"Herr","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2012.05.007_bib5","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: A meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2012.05.007_bib6","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1200\/JCO.1995.13.6.1404","article-title":"Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: Ten-year follow-up of a prospective randomized trial","volume":"13","author":"Herr","year":"1995","journal-title":"J Clin Oncol Off J American Society Of Clinical Oncology"},{"key":"10.1016\/j.urolonc.2012.05.007_bib7","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2012.05.007_bib8","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.eururo.2011.03.051","article-title":"Bacillus Calmette-Guerin without maintenance therapy for high-risk non-muscle-invasive bladder cancer","volume":"60","author":"Herr","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2012.05.007_bib9","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized southwest oncology group study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2012.05.007_bib10","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","article-title":"Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder","volume":"163","author":"Steinberg","year":"2000","journal-title":"J Urol"},{"issue":"Suppl 1","key":"10.1016\/j.urolonc.2012.05.007_bib11","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0268-960X(10)70004-7","article-title":"Lenalidomide mode of action: Linking bench and clinical findings","volume":"24","author":"Davies","year":"2010","journal-title":"Blood Rev"},{"key":"10.1016\/j.urolonc.2012.05.007_bib12","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1586\/era.10.135","article-title":"Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes","volume":"10","author":"Heise","year":"2010","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.urolonc.2012.05.007_bib13","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2012.05.007_bib14","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2012.05.007_bib15","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/1097-0142(197508)36:2<333::AID-CNCR2820360207>3.0.CO;2-1","article-title":"Single and combination chemotherapy for primary murine bladder cancer","volume":"36","author":"Soloway","year":"1975","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2012.05.007_bib16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0090-4295(74)90110-1","article-title":"Chemotherapy of experimental transitional-cell carcinoma","volume":"4","author":"DeKernion","year":"1974","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2012.05.007_bib17","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/0090-4295(75)90367-2","article-title":"Susceptibility of urothelium to neoplastic cellular implantation","volume":"5","author":"Weldon","year":"1975","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2012.05.007_bib18","doi-asserted-by":"crossref","first-page":"8958","DOI":"10.1158\/0008-5472.CAN-09-2045","article-title":"Curcumin potentiates the antitumor effects of bacillus Calmette-Guerin against bladder cancer through the down-regulation of NF-\u03baB and up-regulation of TRAIL receptors","volume":"69","author":"Kamat","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2012.05.007_bib19","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/S0022-5347(17)37589-4","article-title":"Sequential immunocytological evaluation of murine transitional cell carcinoma during intralesional bacillus Calmette-Guerin and interleukin-2 immunotherapy","volume":"147","author":"Sosnowski","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2012.05.007_bib20","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0022-5347(17)38290-3","article-title":"Immunotherapy of murine bladder cancer by irradiated tumor vaccine","volume":"145","author":"Lamm","year":"1991","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2012.05.007_bib21","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/path.1444","article-title":"A novel immunohistochemical method to estimate cell-cycle phase distribution in archival tissue: Implications for the prediction of outcome in colorectal cancer","volume":"201","author":"Scott","year":"2003","journal-title":"J Pathol"},{"key":"10.1016\/j.urolonc.2012.05.007_bib22","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2217\/14796694.1.5.575","article-title":"Lenalidomide: An immunomodulatory drug","volume":"1","author":"Crane","year":"2005","journal-title":"Futures Oncol"},{"key":"10.1016\/j.urolonc.2012.05.007_bib23","doi-asserted-by":"crossref","first-page":"8250","DOI":"10.1158\/0008-5472.CAN-06-1416","article-title":"Neutrophil granulocytes are required for effective bacillus Calmette-Guerin immunotherapy of bladder cancer and orchestrate local immune responses","volume":"66","author":"Suttmann","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2012.05.007_bib24","article-title":"Smac mimetic enables the anticancer action of BCG-stimulated neutrophils through TNF-\u03b1 but not through TRAIL and FasL","author":"Jinesh","year":"2012","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.urolonc.2012.05.007_bib25","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1046\/j.1365-2249.2002.01954.x","article-title":"Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells","volume":"130","author":"Marriott","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.urolonc.2012.05.007_bib26","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0090-4295(97)00067-8","article-title":"Additional bacillus Calmette-Guerin therapy for recurrent transitional cell carcinoma after an initial complete response","volume":"49","author":"Bui","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2012.05.007_bib27","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1002\/(SICI)1097-0142(20000515)88:10<2326::AID-CNCR17>3.0.CO;2-T","article-title":"Predicting the survival of bladder carcinoma patients treated with radical cystectomy","volume":"88","author":"Cheng","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2012.05.007_bib28","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1046\/j.1464-410X.2003.04274.x","article-title":"Results with radical cystectomy for treating bladder cancer: A \u2018reference standard\u2019 for high-grade, invasive bladder cancer","volume":"92","author":"Stein","year":"2003","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2012.05.007_bib29","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood-2002-03-0996","article-title":"Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma","volume":"100","author":"Richardson","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.urolonc.2012.05.007_bib30","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1016\/j.juro.2009.08.020","article-title":"Optimizing orthotopic bladder tumor implantation in a syngeneic mouse model","volume":"182","author":"Chan","year":"2009","journal-title":"J Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814391200169X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814391200169X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:00:47Z","timestamp":1761040847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107814391200169X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S107814391200169X"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2012.05.007","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lenalidomide augments the efficacy of bacillus Calmette-Guerin (BCG) immunotherapy in vivo","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2012.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}